Seth P Lerner

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy
    Kazumasa Matsumoto
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 170:2248-52. 2003
  2. ncbi Treatment of high-risk, non-muscle-invasive bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Nat Clin Pract Urol 3:398-9. 2006
  3. ncbi Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer
    Alvin C Goh
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030 2706, USA
    Urology 72:133-7. 2008
  4. ncbi The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinoma
    Seth P Lerner
    Scott Department of Urology, Dan Duncan Cancer Center, Translational and Molecular Medicine Program, Baylor College of Medicine, 6620 Main Suite 1325, Houston, TX 77030, USA
    Curr Treat Options Oncol 10:267-74. 2009
  5. ncbi Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    Urol Oncol 26:481-5. 2008
  6. ncbi Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma
    Seth P Lerner
    Baylor College of Medicine, Scott Department of Urology, Dan Duncan Cancer Center, Department of Pathology, Methodist Hospital, Houston, Texas 77030, USA
    Curr Opin Urol 18:508-12. 2008
  7. ncbi BCAN Think Tank session 3: Prevention of bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 28:338-42. 2010
  8. ncbi Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 27:155-9. 2009
  9. ncbi Bladder cancer clinical trials
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 23:275-9. 2005
  10. ncbi Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 177:1727-31. 2007

Detail Information

Publications85

  1. ncbi Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy
    Kazumasa Matsumoto
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 170:2248-52. 2003
    ..These patients may benefit from more extensive lymph node dissection and/or combined modality treatment regimens...
  2. ncbi Treatment of high-risk, non-muscle-invasive bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Nat Clin Pract Urol 3:398-9. 2006
  3. ncbi Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer
    Alvin C Goh
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030 2706, USA
    Urology 72:133-7. 2008
    ..The purpose of this study was to examine the application of OCT in augmenting the diagnosis and staging of bladder lesions...
  4. ncbi The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinoma
    Seth P Lerner
    Scott Department of Urology, Dan Duncan Cancer Center, Translational and Molecular Medicine Program, Baylor College of Medicine, 6620 Main Suite 1325, Houston, TX 77030, USA
    Curr Treat Options Oncol 10:267-74. 2009
    ....
  5. ncbi Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    Urol Oncol 26:481-5. 2008
    ..Further studies are necessary to establish the role of neoadjuvant and adjuvant therapy for patient with prostatic stroma invasion...
  6. ncbi Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma
    Seth P Lerner
    Baylor College of Medicine, Scott Department of Urology, Dan Duncan Cancer Center, Department of Pathology, Methodist Hospital, Houston, Texas 77030, USA
    Curr Opin Urol 18:508-12. 2008
    ..To review the current fund of knowledge about prostatic transitional cell carcinoma and the implications for diagnostic and management strategies particularly as they relate to radical cystectomy...
  7. ncbi BCAN Think Tank session 3: Prevention of bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 28:338-42. 2010
    ..These markers, combined with histories of environmental exposure to bladder carcinogens, may provide a tool to identify patients who will benefit from primary prevention...
  8. ncbi Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 27:155-9. 2009
    ..Among all patients randomized to maintenance treatment, we also wanted to identify combinations of baseline covariates in order to define prognostic groups for subsequent worsening-free survival...
  9. ncbi Bladder cancer clinical trials
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 23:275-9. 2005
    ..The present article reviews this important area of clinical trials research...
  10. ncbi Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 177:1727-31. 2007
    ..We explored a large prospective data set from the SWOG 8507 randomized trial of maintenance bacillus Calmette-Guerin to better understand this risk and specifically to assess the impact of timing of recurrence on survival...
  11. ncbi The use and abuse of data: nomograms and talking to patients about clinical medicine
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 25:333-7. 2007
    ..To review the development of nomograms and consortia efforts applying these tools to model outcome predictions associated with radical cystectomy...
  12. ncbi Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA
    BJU Int 108:687-92. 2011
    ..To stratify risk of pathological (p) T2N0 urothelial carcinoma of the bladder after radical cystectomy (RC) based on pathological factors to facilitate the development of adjuvant therapy trials for high-risk patients...
  13. ncbi Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas 77030, USA
    Urology 61:1053-8. 2003
    ..We tested the hypothesis that preoperative plasma levels of uPA and its specific receptor, uPAR, would predict cancer stage and prognosis in patients with transitional cell carcinoma of the bladder...
  14. ncbi Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
    J Urol 185:456-61. 2011
    ..We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival...
  15. ncbi Case-control analysis of dietary folate and risk of bladder cancer
    Matthew B Schabath
    The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Nutr Cancer 53:144-51. 2005
    ..These data may have important implications for cancer prevention; however, large, hypothesis-driven, population-based clinical trials will be required to confirm these findings...
  16. ncbi p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030, USA
    J Clin Oncol 22:1014-24. 2004
    ....
  17. ncbi Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 115:4104-9. 2009
    ....
  18. ncbi Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling
    Jonathan M Levitt
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
    Mol Cancer Ther 9:1128-35. 2010
    ..Further clinical development might be warranted in selected human subjects...
  19. ncbi Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer
    Anita L Sabichi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Clin Cancer Res 14:224-9. 2008
    ..The study aims to evaluate the efficacy and toxicity of fenretinide in preventing tumor recurrence in patients with transitional cell carcinoma (TCC) of the bladder...
  20. ncbi The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 170:2244-7. 2003
    ..An approach using multiple biomarkers may improve the diagnostic accuracy of voided urinary diagnostic tests...
  21. ncbi Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance
    Steven S Shen
    Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    Hum Pathol 37:726-34. 2006
    ..In summary, presence of prostatic TCC involvement and levels of involvement are significant prognostic factors in patients with bladder cancer...
  22. ncbi Combining surgery and chemotherapy for invasive bladder cancer: current and future directions
    Gilad E Amiel
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 6:281-91. 2006
    ..Prospective validation of molecular markers and evaluation of novel therapeutic agents, alone or in combination with established cytotoxic agents, provide hope of better outcomes for bladder cancer patients...
  23. ncbi Neoadjuvant chemotherapy for bladder cancer
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Webster 77598, USA
    Oncology (Williston Park) 21:1673-81; discussion 1686-8, 1691, 1694. 2007
    ..Patients who are either unfit for or refuse radical cystectomy may benefit from neoadjuvant chemotherapy with or without radiation to enable bladder preservation...
  24. ncbi Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    Urology 61:1140-5. 2003
    ..To determine whether p53 and p21 expression in bladder carcinoma in situ (CIS) with or without papillary disease can predict disease recurrence, progression, and survival...
  25. ncbi Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer
    Shahrokh F Shariat
    Baylor Prostate Center, Scott Department of Urology, Baylor College of Medicine, and Methodist Hospital, Houston, Texas 77030-2706, USA
    Urology 61:359-64. 2003
    ..In contrast, a lower preoperative plasma level of IGFBP-3 was associated with lymph node metastasis and poorer clinical outcome after radical cystectomy when adjusted for IGF-I level...
  26. ncbi Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine
    Weiguo Jian
    Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA
    Mol Cancer Ther 8:1772-8. 2009
    ..IHC showed reduced Ki-67 and CD31 and increased cleaved caspase-3 with combination therapy compared with controls. Enzastaurin showed preclinical antitumor activity against human TCC and enhanced the activity of gemcitabine...
  27. ncbi The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder
    Robert S Svatek
    University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Cancer Res 16:4461-7. 2010
    ..Here we address the value of adjuvant chemotherapy in patients undergoing radical cystectomy for UCB in an off-protocol routine clinical setting...
  28. ncbi Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 30:285-9. 2012
    ..To understand the additional benefits of HAL compared with conventional cystoscopy at the patient level and to explore relationships of urine cytology and CIS...
  29. ncbi High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk
    Meng Chen
    Department of Epidemiology and Urology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Carcinogenesis 28:2160-5. 2007
    ..The contributions of these polymorphisms may jointly affect bladder cancer risk through gene-gene and gene-smoking interactions...
  30. ncbi Polymorphisms in XPD exons 10 and 23 and bladder cancer risk
    Matthew B Schabath
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Unit 189, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 14:878-84. 2005
    ....
  31. ncbi Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
    Guru Sonpavde
    Texas Oncology, P A and U S Oncology Research, Houston, TX 77030, USA
    Urol Oncol 27:391-9. 2009
    ..Angiogenesis and VEGF expression correlate with poor outcomes in human urothelial carcinoma. We designed a preclinical study to examine the efficacy of sunitinib alone and in combination with cisplatin against human urothelial carcinoma...
  32. ncbi Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue
    Steven S Shen
    Department of Pathology, The Methodist Hospital and Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer 106:2610-6. 2006
    ..In a previous study the selective ER modulator raloxifene was shown to induce apoptosis in an ERbeta-positive bladder cancer cell line. However, the expression of ERbeta in human bladder cancer has not been thoroughly investigated...
  33. ncbi Racial/ethnic differences in upper-tract urothelial cancer
    G M Monawar Hosain
    Houston VA Health Services Research and Development Center of Excellence, Houston, Texas, USA
    Ethn Dis 22:295-301. 2012
    ..Our study examined the racial/ethnic differences in patients diagnosed with incident UTUC...
  34. ncbi Prostatic transitional cell carcinoma: pathologic features and clinical management
    Steven S Shen
    Department of Pathology, The Methodist Hospital and Weill Medical College of Cornell University, 6565 Fannin Street, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:1155-62. 2007
    ..A rational approach for management of pTCC in patients with bladder cancer will be proposed on the basis of our experience and our review of literature...
  35. ncbi Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort
    Salahaldin A Tahir
    Scott Department of Urology and Department of Pathology, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 12:4872-5. 2006
    ..In the subset of patients with serum PSA of >/=10 ng/mL, the combination of serum cav-1 and biopsy Gleason score has the capacity to predict time to biochemical recurrence...
  36. ncbi Strategies to prevent progression of high-risk bladder cancer at initial diagnosis
    Ja H Ku
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Opin Urol 22:405-14. 2012
    ..As high-risk nonmuscle invasive bladder cancer (NMIBC) has a high propensity to recur and progress, the primary therapeutic goal in patients with high-risk NMIBC is the prevention or delay of disease recurrence and progression...
  37. ncbi A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer
    Anita L Sabichi
    Department of Medicine, Division of Hematology Oncology, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Prev Res (Phila) 4:1580-9. 2011
    ..Our clinical trial results do not show a clinical benefit for celecoxib in preventing NMIBC recurrence but further investigation of COX-2 inhibitors in this setting is warranted...
  38. ncbi Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult
    Mohammadbagher Ziari
    Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:4459-60. 2005
  39. ncbi Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  40. ncbi Stage specific lymph node metastasis mapping in radical cystectomy specimens
    Amnon Vazina
    Scott Department of Urology, Baylor College of Medicine, Methodist and Saint Luke's Episcopal Hospitals, Houston, Texas 77030, USA
    J Urol 171:1830-4. 2004
    ..Extensive LN dissection is essential for the complete removal of disease and accurate staging...
  41. ncbi Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    J Urol 169:938-42. 2003
    ..We could not substantiate a role for COX-2 immunohistochemistry for the staging and prognosis of carcinoma in situ and/or stage T1 transitional cell carcinoma...
  42. ncbi Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer
    Kazumasa Matsumoto
    Scott Department of Urology, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
    Urology 66:441-6. 2005
    ..The association of CAR with E-cadherin and p53 suggests a potential role for CAR in the regulation of urothelium integrity and the cell cycle...
  43. ncbi Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    J Urol 171:626-30. 2004
    ..Urine detection of survivin is an accurate diagnostic test for bladder cancer that retains its efficiency regardless of cancer stage and grade...
  44. ncbi Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer
    Vitaly Margulis
    Department of Urologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 101:114-9. 2009
    ....
  45. ncbi Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder cancer
    Arup Chakraborty
    Department of Pediatrics, Section of Leukocyte Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Urology 63:177-83. 2004
    ..In neutrophils, G-CSF acts through its receptor to enhance adhesion and migration. A significant fraction of bladder carcinoma has been reported to express both G-CSF and G-CSFR...
  46. ncbi Dietary carotenoids and genetic instability modify bladder cancer risk
    Matthew B Schabath
    Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    J Nutr 134:3362-9. 2004
    ..18; 95% CI, 1.13-4.22). This study provides evidence of a preventive role for carotenoids in bladder cancer, and these data may have important implications for cancer prevention, especially for individuals susceptible to DNA damage...
  47. ncbi Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma
    Roberto Casella
    the Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Cancer 95:2494-9. 2002
    ..CONCLUSIONS: The current findings suggest that urinary levels of uPA, but not uPAR, are related to the risk of bladder carcinoma. The study confirmed the central role of urinary cytology in the noninvasive diagnosis of bladder carcinoma...
  48. ncbi Centrosomal abnormality is common in and a potential biomarker for bladder cancer
    Feng Jiang
    Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 106:661-5. 2003
    ..Centrosomal abnormalities appear to be intrinsic to aneuploidy and tumorigenesis and may be potential markers for early detection of bladder cancer...
  49. ncbi Bladder cancer screening program for a petrochemical cohort with potential exposure to beta-napthylamine
    Sarah A Felknor
    University of Texas Health Science Center at Houston, School of Public Health, Southwest Center for Occupational and Environmental Health, Houston, TX, USA
    J Occup Environ Med 45:289-94. 2003
    ..Original personnel records are often incomplete, making cohort identification important. Personal contact and follow-up are key elements of successful recruitment and retention...
  50. ncbi Bladder cancer detection, treatment and outcomes: opportunities and challenges
    David M Latini
    Scott Department of Urology and Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Urology 75:334-9. 2010
    ..Increasing national attention to BlCa is likely to improve disease burden and patient quality of life...
  51. ncbi Innovations in radical cystectomy and pelvic lymph node dissection
    Lambros Stamatakis
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Semin Oncol 39:573-82. 2012
    ..Anatomic pelvic and iliac lymphadenectomy is crucial for precise pathologic staging and may improve patient survival by removing micrometastatic disease...
  52. ncbi Alternatives to cytology in the management of non-muscle invasive bladder cancer
    Gilad E Amiel
    Baylor College of Medicine, 6560 Fannin Street, Suite 2100, Houston, TX 77030, USA
    Curr Treat Options Oncol 5:377-89. 2004
    ....
  53. ncbi Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study
    Anita L Sabichi
    University of Texas M D Anderson Cancer Center, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 12:2178-84. 2006
    ..Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue...
  54. ncbi Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer
    Ben Andrews
    Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    J Urol 167:1475-81. 2002
    ..Levels of IL-6 and IL-6sR were associated with cancer stage and metastases, and were strong independent predictors of disease recurrence and disease specific survival...
  55. ncbi Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro
    C T F Freund
    Scott Department of Urology, Baylor College of Medicine, and The Methodist Hospital, 6560 Fannin, Suite 2100, Houston, TX 77030, USA
    Urol Oncol 21:197-205. 2003
    ..Additional studies exploring the role of methotrexate in enhancing the tk-GCV system are required. Investigation of other, potentially more synergistic chemotherapeutic agents in combination with tk-GCV is warranted...
  56. ncbi Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder
    Mohammadbagher Ziari
    Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:4458-9. 2005
  57. ncbi Application of new technology in bladder cancer diagnosis and treatment
    Alvin C Goh
    Scott Department of Urology, Baylor College of Medicine, 6620 Main Street, Suite 1325, Houston, TX 77030, USA
    World J Urol 27:301-7. 2009
    ..We aim to provide an overview of the strengths and weaknesses of these imaging modalities and examine their potential impact on the diagnosis and management of bladder cancer...
  58. ncbi Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk
    Hua Zhao
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Urol 169:714-7. 2003
    ..Because insulin-like growth factors (IGFs) and their binding proteins have been implicated in the development of prostate, breast, colon and lung cancer, we examined the role of IGF-1 and IGF binding protein-3 levels in bladder cancer risk...
  59. ncbi Raloxifene Inhibits Growth of RT4 Urothelial Carcinoma Cells via Estrogen Receptor-Dependent Induction of Apoptosis and Inhibition of Proliferation
    Kristi L Hoffman
    Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA
    Horm Cancer 4:24-35. 2013
    ..These results indicate that antiestrogens may be useful therapeutics in the treatment of bladder cancer by targeting ER and inhibiting growth via multiple mechanisms...
  60. ncbi Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review
    Ja Hyeon Ku
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    BJU Int 110:630-6. 2012
    ..The clinical utility of urine survivin as a bladder tumour marker identified in the present study remains to be elucidated...
  61. ncbi Advances in diagnosis and therapy of transitional cell carcinoma of the bladder
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA
    Urol Oncol 24:324-5. 2006
  62. ncbi Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder
    Craig G Rogers
    Bladder Cancer Research Consortium, James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287-2101, USA
    J Urol 175:2048-53; discussion 2053. 2006
    ..Patients with bladder TCC and SCC share similar stage specific clinical outcomes...
  63. ncbi Cancer specific outcomes in patients with pT0 disease following radical cystectomy
    Ganesh S Palapattu
    James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    J Urol 175:1645-9; discussion 1649. 2006
    ..We assessed clinical outcomes in patients found to have no evidence of disease, ie pT0, in the cystectomy specimen following radical cystectomy for transitional cell carcinoma...
  64. ncbi Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy
    Yair Lotan
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9110, USA
    J Clin Oncol 23:6533-9. 2005
    ..We hypothesized that bladder cancer patients with associated lymphovascular invasion (LVI) are at increased risk of occult metastases...
  65. ncbi Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival
    Patrick J Bastian
    The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    BJU Int 101:450-4. 2008
    ....
  66. ncbi Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical School 5323 Harry Hines Blvd, Dallas, Texas 75390 9110, USA
    Eur Urol 48:69-76. 2005
    ..To test the hypothesis that elevated urinary levels of soluble E-cadherin (sE-cadherin) would aid in the detection of transitional cell carcinoma (TCC) of the urinary bladder...
  67. ncbi Perioperative chemotherapy in locally advanced bladder cancer
    Walter M Stadler
    Department of Medicine, Section of Hematology/Oncology and Urology, University of Chicago, Chicago, IL 60637, USA
    Lancet 361:1922-3. 2003
  68. ncbi Neoadjuvant chemotherapy preceding cystectomy for bladder cancer
    Guru Sonpavde
    Texas Oncology, P A and US Oncology Research, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Opin Pharmacother 9:1885-93. 2008
    ..Occult micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced, muscle-invasive transitional cell carcinoma of the bladder...
  69. ncbi Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Eur Urol 51:137-49; discussion 149-51. 2007
    ..We compared clinical and pathologic staging in a large, contemporary, consecutive series of patients who were treated with radical cystectomy and pelvic lymphadenectomy, and determined the effect of stage discrepancy on outcomes...
  70. ncbi A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome
    Matthew E Nielsen
    The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    BJU Int 100:1015-20. 2007
    ....
  71. ncbi Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Cancer 112:315-25. 2008
    ....
  72. ncbi Nomograms provide improved accuracy for predicting survival after radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, and The Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    Clin Cancer Res 12:6663-76. 2006
    ....
  73. ncbi Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy
    Matthew E Nielsen
    The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    Eur Urol 51:699-706; discussion 706-8. 2007
    ..The aim of our study was to assess the impact of patient age on pathological characteristics and recurrence-free and disease-specific survival following RC...
  74. ncbi Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Urol 176:2414-22; discussion 2422. 2006
    ..We present the characteristics and outcomes of a large, contemporary, consecutive series of patients treated with radical cystectomy and pelvic lymphadenectomy for transitional cell carcinoma of the bladder...
  75. ncbi Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy
    Amit Gupta
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 71:302-7. 2008
    ..The aim of the present study was to assess the pathologic features and clinical outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma (UCBC) treated with radical cystectomy...
  76. ncbi Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study
    Jochen Walz
    Cancer Prgonosis and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    BJU Int 101:1356-61. 2008
    ....
  77. ncbi Precystectomy nomogram for prediction of advanced bladder cancer stage
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    Eur Urol 50:1254-60; discussion 1261-2. 2006
    ..To evaluate precystectomy prediction of pT and pN stages at cystectomy...
  78. ncbi Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    J Urol 176:1354-61; discussion 1361-2. 2006
    ....
  79. ncbi Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Eur Urol 51:152-60. 2007
    ..The aim of this study was to assess whether presence of concomitant CIS has a detrimental effect on cancer control after radical cystectomy...
  80. ncbi Molecular markers in bladder cancer
    Shahrokh F Shariat
    Department of Urology, UT Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Curr Opin Urol 18:1-8. 2008
    ..Bladder cancer is a diverse disease whose molecular phenotypes are being elucidated. In this review, we summarize currently known molecular pathways and associated markers in bladder cancer...
  81. ncbi Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9110, USA
    Urology 68:538-42. 2006
    ..001). CONCLUSIONS: Disease control seemed durable for patients with pathologic CIS only at radical cystectomy in the absence of metastases to the lymph nodes, even in the case of failure after intravesical therapy...
  82. ncbi Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1
    Isaac Yi Kim
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Res 64:7355-60. 2004
    ....
  83. ncbi Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma
    Guru Sonpavde
    U S Oncology Research, Webster, Texas, USA
    Urology 69:1221-6. 2007
    ..To evaluate estrogen receptors as a therapeutic target for human bladder cancer...
  84. ncbi Chemoprevention of bladder cancer
    Dragan J Golijanin
    Urology Department, University of Rochester Medical Center, 601 Elmwood Avenue, P.O. Box 656, Rochester, NY 14642, USA
    World J Urol 24:445-72. 2006
  85. ncbi Editorial comment on: Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light
    Seth P Lerner
    Eur Urol 52:1708-9. 2007